Figure 10. Exploration of potential chemotherapeutic compounds for HCC in the different risk subgroups. The drug sensitivity evaluation of (A) VX-680; (B) TGX221; (C) Sorafenib; (D) Roscovitine; (E) Pyrimethamin; (F) Parthenolide; (G) KIN001-135; (H) GW843682X; (I) GNF-2; (J) Erlotinib; (K) Crizotinib and (L) CGP-082996.